The landscape for Dr. Barbara Sturm, the renowned German skincare company, has undergone a significant shift since its integration into the Puig portfolio in January 2024. This strategic move, placing the brand alongside luxury labels such as Rabanne and Charlotte Tilbury, promises an amplified commitment to scientific inquiry, the refinement of existing formulations, and the unveiling of novel product offerings. Dr. Sturm herself affirms that the acquisition has provided expanded resources and autonomy, enabling deeper exploration into research and development, particularly in areas concerning inflammation, cellular regeneration, and the science of longevity. The collaboration has also facilitated a more structured global expansion, bolstering operational and strategic support, thereby empowering the brand to prioritize groundbreaking innovation and consumer education.
Puig's acquisition of Dr. Barbara Sturm strengthens its burgeoning skincare division, which, despite being the smallest, demonstrates the second-fastest growth within the group. This segment reported sales of €551 million in 2025 and includes other prominent skincare brands like Uriage and Apivita. Dr. Barbara Sturm marks Puig's inaugural luxury skincare acquisition that is both scientifically underpinned and physician-founded. Since its inception in 2014, Dr. Sturm's brand has cultivated a devoted following for its molecular skincare approach.
While the exact financial details of the transaction remain undisclosed, reports at the time of the acquisition estimated Dr. Barbara Sturm's sales at approximately €70 million. Marc Puig, Chairman and CEO of Puig, commented on the long-term vision for integrating such brands, emphasizing the time required to realize their full potential within the conglomerate.
The acquisition represents Puig's investment in a key trend dominating the skincare industry: a demand for products grounded in scientific evidence, ingredient efficacy, and demonstrable results. Seb Barbero, SVP of consumer and retail M&A at EY Capital Advisors, noted that brands offering transparent, science-backed claims and authentic engagement are poised for sustained success.
In her redefined capacity, Dr. Sturm has transitioned from daily operational oversight to concentrate on product research and development, serving as Chief Product Development Officer and brand ambassador while retaining a minority stake. She expresses satisfaction with relinquishing full ownership, emphasizing her desire for the brand's growth and her enthusiasm for observing its evolving potential. The integration into Puig's vast scientific research capabilities has significantly amplified the brand's capacity for rigorous product trials and the exploration of new ingredients.
Dr. Sturm maintains a strong connection with her patient base and the wider community, allowing real-world skin concerns to continue driving innovation. Current research directions include delving into cell signaling and advanced regenerative pathways, with a holistic approach that integrates lab-based findings with consumer health behaviors, wellness data, and biological insights.
Reflecting on her pioneering work, Dr. Sturm recalled developing the "vampire facial" in 2003, a treatment that has since become widely adopted. She identifies inflammation as a fundamental aspect of skincare, asserting that minimizing it safeguards skin health, cellular structure, immune function, and long-term vitality. Building on this principle, her latest innovations include the Exoso-Metic Face Serum, which harnesses immunomodulatory exosomes to facilitate cellular communication and repair, moving beyond superficial skin benefits to address cellular wellness. This approach signifies a paradigm shift from conventional cosmetics to advanced cellular repair.
Addressing the saturated skincare market, particularly regarding ingredients like peptides and exosomes, Dr. Sturm underscored the distinctiveness of her new product developments. The Exoso-Metic collection utilizes lab-synthesized exosomes and epidermal growth factors, produced through recombinant protein technology. These bioidentical components, crafted ethically and under strict controls, deliver potent results by calming inflammation and rejuvenating skin at a cellular level. This technology is particularly beneficial for those seeking advanced anti-aging support and superior ingredient science to stimulate collagen and enhance elastin production.
The Peptide Serum, another recent launch, features a high concentration of biomimetic peptides designed to boost collagen production and support the skin's extracellular matrix. Unlike topical collagen, these peptides initiate deeper cascades, leading to visible improvements. A key ingredient, octapeptide-3, works to relax muscle contractions, offering a Botox-like effect, while other peptides act as "personal trainers" for the skin, encouraging sustained collagen synthesis and storage. Clinical data indicates that the Peptide Serum can improve collagen production by up to 63% and elastin production by up to 90%. The timing of these product launches aligns with a growing consumer understanding of exosomes and peptides at a cellular level.
Dr. Sturm clarified that the brand's development was never singularly focused on an acquisition. Her drive stemmed from a competitive and ambitious spirit, aiming to solve genuine skin biology issues through integrity, transparency, and clinical validation. The decision to partner with Puig was influenced by the conglomerate's family-led ethos and shared values regarding innovation, excellence, and a long-term perspective. She emphasizes that the partnership felt right, allowing the brand to scale responsibly without compromising its scientific foundation or luxury positioning, leveraging Puig's experience in nurturing beauty brands globally.
For aspiring brands contemplating acquisition, Dr. Sturm advises prioritizing the creation of a truly distinctive and impactful product, rather than building with the sole intent of being acquired. She also stresses the importance of robust financial management and operational structures, emphasizing the need for a skilled CFO and meticulous oversight of administrative details, even suggesting forensic checks on financial figures. Her personal experience with Keyhaven Capital in 2019, which led to the hiring of a CMO and formal business structuring, highlights the importance of preparing for such transitions. While acknowledging the emotional aspect of relinquishing some control, Dr. Sturm feels secure in the continued respect for the brand's values, science, and integrity, remaining deeply involved in critical areas. She envisions her tenure with the brand lasting at least five years, with openness to extending beyond that period.
